Тоцилізумаб у лікуванні ювенільного ревматоїдного артриту
Bibliographic record
Abstract
У розвитку ревматичних хвороб, особливо при ювенільному ревматоїдному артриті, доведена важлива роль окремих цитокінів, найважливішими серед яких є інтерлейкін-1, інтерлейкін-6 та фактор некрозу пухлини α. Новим словом у лікуванні даної групи хвороб є імунобіологічні препарати. Препарат гуманізованих антитіл проти рецепторів інтерлейкіну-6 тоцилізумаб є високоефективним та безпечним засобом для лікування системної та поліартикулярної форми ювенільного ревматоїдного артриту. 1. Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. и др. Динамика лабораторных маркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом // Научно-практическая ревматология. — 2011. — № 3. — С. 14-19.2. Бережний В.В., Марушко Т.В., Роменкевич І.В. Стан надання кардіоревматологічної допомоги дітям України за 2009 р. // Современная педиатрия. — 2010. — № 5(33). — С. 14-18.3. Уніфікований клінічний протокол медичної допомоги дітям, хворим на ювенільний артрит. Затверджений Наказом МОЗ України № 832 від 22.10.12.4. Brunner H., Ruperto N., Zuber Z. et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial [abstract no. 1597] // Arthritis Rheum. — 2012. — Vol. 64. — P. S682.5. Cassidy J.T., Petty R.E. Textbook of Pediatric Rheumatology. 5th ed. — Philadelphia: W.B. Saunders Company, 2005. — 792 p. 6. De Benedetti F., Brunner H.I., Ruperto N. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis // N. Engl. J. Med. — 2012. — Vol. 367(25). — P. 2385-2395. 7. Frampton F.E. Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis // Pediatric Drugs. — Vol. 15, Issue 6. — P. 515-531.8. Genentech Inc. Actemra® (tocilizumab) injection, for intravenous infusion. US prescribing information. 2013. http://www.gene.com/ download/pdf/actemra_prescribing.pdf. Accessed 2 Sep 2013.9. Henter J.I., Horne A., Aricó M., Egeler R.M., Filipovich A.H. et al. Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis // Pediatric Blood Cancer. — 2007. — Vol. 48. — P. 124-131.10. Hoffman-La Roche. A study of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis [ClinicalTrials.gov identifier NCT00988221]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http://clinicaltrials.gov/ct2/show/record/NCT00988221. Accessed 2 Sep 2013.11. Hoffman-La Roche. Roche trials database. Clinical trial result information. Protocol number: WA19977. 2012. http://www.roche-trials.com/studyResultGet.action?studyResultNumber=WA19977. Accessed 2 Sep 2013. 21.12. Immonen K., Savolainen A., Kautiainen H., Hakala M. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis // Journal of Rheumatology. — 2008. — Vol. 35, № 5. — P. 907-912. 13. Packard R., Libby P. Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction // Clinical Chemistry. — 2008. — Vol. 54. — P. 24-38. 14. Petty R.E., Southwood T.R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 // Journal of Rheumatology. — 2004. — Vol. 31. — P. 390-392. 15. Ravelli A., Martini A. Juvenile idiopathic arthritis // Lancet. — 2007. — Vol. 369. — P. 767-778. 16. Roche Pharma AG. RoActemra 20 mg/mL concentrate for solution for infusion. EU summary of product characteristics 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000955/WC500054890.pdf. Accessed 2 Sep 2013.17. Stéphan J.L., Koné-Paut I., Galambrun C., Mouy R., Bader-Meunier B., Prieur A.M. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients // Rheumatology. — 2001. — Vol. 40, № 11. — P. 1285-1292. 18. Tanaka T., Ogata A., Narazaki M. Tocilizumab for treatment of rheumatoid arthritis // Expert rewiew in clinical immunology. — 2010. — Vol. 6. — P. 843-854. 19. Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic onset of juvenile idiopathic arthritis: a randomized, double blind, placebo-controlled, withdrawal phase III trial // Lancet. — 2008. — Vol. 371. — P. 998-1006.20. Yoshimura T., Sonoda K., Ohguro N. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis // Rheumatology. — 2009. — Vol. 48 (4). — P. 347-354. 21. Zhang X., Morcos P.N., Saito T. et al. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis // Expert. Rev. Clin. Pharmacol. — 2013. — Vol. 6(2). — P. 123-137.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.003 |
| Insufficient payload (model declined to judge) | 0.006 | 0.010 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; both teacher heads agree on what is shown here.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".